GlassScriptPhysician profile
Christina Price-Jackson
NPI 1194189571
$3,795.04
in general payments reported to CMS, 2019-2025
27 companies · $25.81 in 2025
The $25.81 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $633 · 2021: $1,960 · 2022: $848 · 2024: $95.66 · 2025: $25.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,333.76 | 2021 | |
| Amgen INC. | $322.36 | 2019-2022 | |
| Novo Nordisk INC | $295.65 | 2019-2022 | |
| Abbvie INC. | $209.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $181.69 | 2019-2022 | |
| Abbott Laboratories | $159.72 | 2021-2022 | |
| Lilly USA, LLC | $158.02 | 2019-2022 | |
| Astellas Pharma US INC | $155.71 | 2019-2021 | |
| Amarin Pharma, INC. | $154.83 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $122.31 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $110.89 | 2022 | |
| Glaxosmithkline, LLC. | $81.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.12 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $51.54 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $51.34 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Hologic Sales and Service, LLC | $51.09 | 2022-2024 | Aptima |
| Janssen Pharmaceuticals, INC | $50.00 | 2019 | |
| Genentech USA, INC. | $37.90 | 2020-2021 | |
| Scynexis, INC. | $24.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.58 | 2022 | |
| Pfizer INC. | $19.97 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.03 | 2022 | |
| Exact Sciences Corporation | $14.10 | 2024 | Cologuard Collection Kit |
| Phadia US INC. | $11.88 | 2019 | |
| Genzyme Corporation | $11.81 | 2021 | |
| Allergan, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Price-Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.